Sugi Predict

Sugi Predict / Compounds / SCHEMBL172526

SCHEMBL172526

SCHEMBL172526

CC(C)(C)OC(=O)CC[C@@H](N)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC1A1 P43005 2/20 0.52
▸ GSR P00390 2/20 0.52
▸ GRM8 O00222 1/20 0.52
▸ GRM6 O15303 1/20 0.52
▸ GRIN2D O15399 1/20 0.52
▸ GRIN3B O60391 1/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ GRIK1 P39086 1/20 0.52
▸ GRM5 P41594 1/20 0.52
▸ GRIA1 P42261 1/20 0.52
▸ GRIA2 P42262 1/20 0.52
▸ GRIA3 P42263 1/20 0.52
▸ SLC1A3 P43003 1/20 0.52
▸ SLC1A2 P43004 1/20 0.52
▸ GRIA4 P48058 1/20 0.52
▸ GRIN1 Q05586 1/20 0.52
▸ GRIN2A Q12879 1/20 0.52
▸ GRIK2 Q13002 1/20 0.52
▸ GRIK3 Q13003 1/20 0.52
▸ GRIN2B Q13224 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130831 1.00 SLC1A1 (0.52) SLC1A1GSRGRM8GRM6GRIN2D
SCHEMBL1411236 1.00 SLC1A1 (0.52) SLC1A1GSRGRM8GRM6GRIN2D
SCHEMBL28096239 0.98 SLC1A1 (0.50) SLC1A1GSRGRM8GRM6GRIN2D
Water SCHEMBL21597885 0.98 SLC1A1 (0.50) SLC1A1GSRGRM8GRM6GRIN2D
Water SCHEMBL21597884 0.98 SLC1A1 (0.50) SLC1A1GSRGRM8GRM6GRIN2D
SCHEMBL28096238 0.98 SLC1A1 (0.50) SLC1A1GSRGRM8GRM6GRIN2D
Hydrochloric Acid SCHEMBL27912753 0.98 SLC1A1 (0.50) SLC1A1GSRGRM8GRM6GRIN2D
Hydrochloric Acid SCHEMBL2124738 0.98 SLC1A1 (0.50) SLC1A1GSRGRM8GRM6GRIN2D
SCHEMBL2218978 0.89 GSR (0.46) SLC1A1GSRGRM8GRM6GRIN2D
SCHEMBL12463782 0.89 GSR (0.46) SLC1A1GSRGRM8GRM6GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112745508-B Hydrophilic, antibacterial and anti-protein adhesion silicone rubber and preparation method thereof 中国科学院理化技术研究所 2022-11-18 — — CN claimed
WO-2020182227-A1 PREPARATION METHOD FOR HIGH PURITY LIRAGLUTIDE SIDE CHAIN 美药星（南京）制药有限公司 2020-09-17 — — WO claimed
US-20260042867-A1 ANTIBODY REPURPOSING SRI INTERNATIONAL (US) 2026-02-12 — — US disclosed
CN-119930814-A D-peptide compounds directed against VEGF 反射制药有限公司 2025-05-06 — — CN disclosed
EP-4536682-A2 ANTIBODY REPURPOSING SRI International (US) 2025-04-16 — — EP disclosed
CN-111295373-B Compositions and methods for treating brain injury 阿泽凡药物公司 2024-12-10 — — CN disclosed
US-20240293549-A1 Conjugates And Conjugating Reagents POLYTHERICS LIMITED (GB) 2024-09-05 — — US disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 — — EP disclosed
US-20240216513-A1 FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE NOVARTIS AG (CH) 2024-07-04 — — US disclosed
CN-118178417-A Antiproliferative compounds and second active agents for the treatment of multiple myeloma 细胞基因公司 2024-06-14 — — CN disclosed
EP-4380629-A1 LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP Technische Universität München (DE) 2024-06-12 — — EP disclosed
US-20080051603-A1 Process for the preparation of poly-alpha-glutamic acid and derivatives thereof CELL THERAPEUTICS, INC. (US) 2008-02-28 — — US disclosed
WO-2007144140-A1 A PROCESS FOR THE PREPARATION OF POLY-ALFA-GLUTAMIC ACID AND DERIVATIVES THEREOF CELL THERAPEUTICS INC. - SEDE SECONDARIA (IT) 2007-12-21 — — WO disclosed
EP-1867657-A1 Process for the preparation of poly-a-glutamic acid and derivatives thereof Cell Therapeutics Europe S.R.L. (IT) 2007-12-19 — — EP disclosed
WO-2007062664-A2 ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES NUEVOLUTION A/S (DK) 2007-06-07 — — WO disclosed
EP-0635026-B1 NOVEL LIPOPHILIC OLIGOPEPTIDES WITH IMMUNOMODULATING ACTIVITY IAF BIOCHEM INT (CA) 1999-11-10 — — EP disclosed
US-5688771-A Lipophilic oligopeptides with immunomodulating activity BIOCHEM PHARMA INC. (CA) 1997-11-18 — — US disclosed
CN-1122577-A Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders DU PONT MERCK PHARMA (US) 1996-05-15 — — CN disclosed
WO-1993020100-A1 NOVEL LIPOPHILIC OLIGOPEPTIDES WITH IMMUNOMODULATING ACTIVITY BIOCHEM PHARMA INC. (CA) 1993-10-14 — — WO disclosed
US-5108990-A GLUTAMIC ACID DERIVATIVES ROUSSEL UCLAF (FR) 1992-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216513-A1 FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE FASN, FABP1, SCD SLC1A1 3351/4885GSR 1644/4885GRM8 4020/4885
US-20240293549-A1 Conjugates And Conjugating Reagents ANPEP, NGLY1, PCTP SLC1A1 2953/4885GSR 2908/4885GRM8 4455/4885
US-20260042867-A1 ANTIBODY REPURPOSING CD47, SSB, IGSF11 SLC1A1 1582/4885GSR 4736/4885GRM8 2869/4885
US-20080051603-A1 Process for the preparation of poly-alpha-glutamic acid and derivatives thereof GLUL, QPCT, GABRP SLC1A1 73/4885GSR 1698/4885GRM8 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.